Signaling transduction pathways and networks have recently proven to be attractive targets for cancer therapy. Gleevac, herceptin (TM), C225, Irressa, and CCI779 have all induced remarkable, non-toxic responses in a subset of patients where abnormalities in the appropriate signaling pathway are present, respectively, bcrabl (Gleevac), ErbB-2 (also known as HER-2/neu, herceptin(TM)), EGFR (C225 and Irressa), and the PI-3K pathway (CCI779). The development and utilization of novel molecular therapeutics requires a detailed understanding of the signaling aberrations present in tumors. This program project grant (PPG) aims at understanding signaling pathways of a few key molecules that play critical roles in breast tumor progression. The immediate goals of this PPG are to characterize the ErbB-2/PI-3K/Akt signaling transduction pathways or """"""""network of nodes"""""""" in the initiation and progression of breast cancer through understanding these signaling pathways in details, and their contributions to development of breast cancer. This PPG consists of four interactive projects supported by one administrative core. Each of the four projects has its own unique set of specific aims that target at the common theme and are interdependent on components of other projects in the PPG. Project 1 focuses on the role of Akt-mediatefl signaling and its contribution to the cell growth and tumor progression in breast cancer cells. Project 1 will evaluate two critical snbstrates of Akt, namely, p21 cip1/WAF1and MDM2. Project 2 plans to exploit two well-characterized transgenic mouse models expressing either mutant PyV mT de-coupled from the PI-3K pathway or activated erbB-2 in themammary epithelium. Project 3 will test the hypothesis that the p85 regulatory subunit of PI-3K plays a critical role in the regulation of breast cancer initiation and progression through its ability to recruit Racl, Pakl and other interacting molecules. Project 4 will investigate GJM deregulation and antiapoptosis by ErbB-2 in breast cancer cells. The hypothesis to be tested is that the effects of ErbB-2 on multiple GJM regulators (p21cip1/WAF1 upregulation, Cdc2-Y15-p and survivin upregulation) can lead to GJM deregulation that contributes to anti-apoptosis. The long-term goals of this PPG are to improve strategies for the diagnosis and treatment of human breast cancer, especially in providing knowledge for better design rationale drugs to combat breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA099031-02S1
Application #
6794930
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Rosenfeld, Bobby
Project Start
2003-04-01
Project End
2008-03-31
Budget Start
2004-04-16
Budget End
2005-03-31
Support Year
2
Fiscal Year
2004
Total Cost
$49,742
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Microbiology/Immun/Virology
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yamaguchi, H; Du, Y; Nakai, K et al. (2018) EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene 37:208-217
Joshi, Sonali; Yang, Jun; Wang, Qingfei et al. (2017) 14-3-3? loss impedes oncogene-induced mammary tumorigenesis and metastasis by attenuating oncogenic signaling. Am J Cancer Res 7:1654-1664
Mazumdar, Abhijit; Poage, Graham M; Shepherd, Jonathan et al. (2016) Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat 158:441-54
Haukaas, Tonje H; Euceda, Leslie R; Giskeødegård, Guro F et al. (2016) Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer Metab 4:12
Lim, Seung-Oe; Li, Chia-Wei; Xia, Weiya et al. (2016) EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Res 76:1284-96
Ko, How-Wen; Lee, Heng-Huan; Huo, Longfei et al. (2016) GSK3? inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget 7:57131-57144
Wang, Yan; Hsu, Jung-Mao; Kang, Ya'an et al. (2016) Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. Cancer Res 76:7049-7058
Du, Yi; Yamaguchi, Hirohito; Wei, Yongkun et al. (2016) Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med 22:194-201
Li, Chia-Wei; Xia, Weiya; Lim, Seung-Oe et al. (2016) AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res 76:1451-62
Mitra, Shreya; Federico, Lorenzo; Zhao, Wei et al. (2016) Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. Oncotarget 7:40252-40265

Showing the most recent 10 out of 204 publications